Hookipa Pharma Stock Performance
| HOOK Stock | USD 1.06 0.03 2.91% |
On a scale of 0 to 100, Hookipa Pharma holds a performance score of 15. The company retains a Market Volatility (i.e., Beta) of -0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Hookipa Pharma are expected to decrease at a much lower rate. During the bear market, Hookipa Pharma is likely to outperform the market. Please check Hookipa Pharma's maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Hookipa Pharma's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Hookipa Pharma are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite fragile basic indicators, Hookipa Pharma disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2024-07-10 |
1 | HOOKIPA Pharma Inc. stock trendline breakdown - 2025 Top Gainers High Conviction Buy Zone Alerts - newser.com | 11/14/2025 |
2 | Can HOOKIPA Pharma Inc. stock reach 100 price target - July 2025 Earnings Smart Investment Allocation Insights - newser.com | 11/17/2025 |
3 | Acquisition by Aldag Jorn of 47824 shares of Hookipa Pharma at 3.0 subject to Rule 16b-3 | 11/21/2025 |
4 | AEW Full Gear 2025 The Biggest Questions Coming Out Of The Show | 11/24/2025 |
5 | Disposition of 25172 shares by Peters Malte of Hookipa Pharma at 0.8217 subject to Rule 16b-3 | 12/31/2025 |
6 | Disposition of 2205 shares by Matushansky Igor of Hookipa Pharma at 2.49 subject to Rule 16b-3 | 01/30/2026 |
7 | Hooked Protocol Hits 24 Hour Trading Volume of 3.06 Million | 02/09/2026 |
| Begin Period Cash Flow | 117.5 M | |
| Total Cashflows From Investing Activities | -194 K |
Hookipa Pharma Relative Risk vs. Return Landscape
If you would invest 87.00 in Hookipa Pharma on November 13, 2025 and sell it today you would earn a total of 19.00 from holding Hookipa Pharma or generate 21.84% return on investment over 90 days. Hookipa Pharma is currently generating 0.3445% in daily expected returns and assumes 1.7428% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Hookipa, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hookipa Pharma Target Price Odds to finish over Current Price
The tendency of Hookipa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.06 | 90 days | 1.06 | near 1 |
Based on a normal probability distribution, the odds of Hookipa Pharma to move above the current price in 90 days from now is near 1 (This Hookipa Pharma probability density function shows the probability of Hookipa Stock to fall within a particular range of prices over 90 days) .
Hookipa Pharma Price Density |
| Price |
Predictive Modules for Hookipa Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hookipa Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Hookipa Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Hookipa Pharma is not an exception. The market had few large corrections towards the Hookipa Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hookipa Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hookipa Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | -0.61 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | 0.12 |
Hookipa Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hookipa Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hookipa Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hookipa Pharma has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 43.95 M. Net Loss for the year was (43.5 M) with loss before overhead, payroll, taxes, and interest of (50.47 M). | |
| Hookipa Pharma currently holds about 117.92 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hookipa Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Hooked Protocol Hits 24 Hour Trading Volume of 3.06 Million |
Hookipa Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hookipa Stock often depends not only on the future outlook of the current and potential Hookipa Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hookipa Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.5 M | |
| Cash And Short Term Investments | 39.7 M |
Hookipa Pharma Fundamentals Growth
Hookipa Stock prices reflect investors' perceptions of the future prospects and financial health of Hookipa Pharma, and Hookipa Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hookipa Stock performance.
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (8.85) % | ||||
| Current Valuation | (20.98 M) | ||||
| Shares Outstanding | 9.93 M | ||||
| Price To Earning | 12.06 X | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 1.40 X | ||||
| Revenue | 43.95 M | ||||
| Gross Profit | (50.47 M) | ||||
| EBITDA | (40.85 M) | ||||
| Net Income | (43.5 M) | ||||
| Cash And Equivalents | 117.92 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 875 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.48 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (76.98 M) | ||||
| Earnings Per Share | (4.83) X | ||||
| Market Capitalization | 13.07 M | ||||
| Total Asset | 82.55 M | ||||
| Retained Earnings | (412.76 M) | ||||
| Working Capital | 56.01 M | ||||
| Current Asset | 26.61 M | ||||
| Current Liabilities | 25.01 M | ||||
About Hookipa Pharma Performance
By examining Hookipa Pharma's fundamental ratios, stakeholders can obtain critical insights into Hookipa Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Hookipa Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (48.83) | (51.27) | |
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.98) | (1.03) |
Things to note about Hookipa Pharma performance evaluation
Checking the ongoing alerts about Hookipa Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hookipa Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hookipa Pharma has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 43.95 M. Net Loss for the year was (43.5 M) with loss before overhead, payroll, taxes, and interest of (50.47 M). | |
| Hookipa Pharma currently holds about 117.92 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hookipa Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Hooked Protocol Hits 24 Hour Trading Volume of 3.06 Million |
- Analyzing Hookipa Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hookipa Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Hookipa Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hookipa Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hookipa Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hookipa Pharma's stock. These opinions can provide insight into Hookipa Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.83) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.